Whole Blood Assay
Whole Blood Assay - Related Videos
07:03
An in vivo Assay to Test Blood Vessel Permeability
0 Views •
Cited by 335 •
2013
We are presenting an in vivo assay to test blood vessel permeability. This assay is based on intravenous injection of a dye and subsequent visualization of its diffusion into interstitial spaces.
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
0 Views •
2012
Demonstration of a rapid quantitative assay of the inhibition of blood coagulation by the low-molecular-weight-heparin, enoxaparin. The contribution of enoxaparin is assessed by removing its influence through digestion with heparinase. A fuller description of the assay is detailed in our published paper.1 The assay still requires clinical confirmation.
14:45
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
0 Views •
Cited by 14 •
2012
In this report, we demonstrate the staining and analysis steps of a phenotyping assay performed on fresh whole blood to enumerate major innate and adaptive leukocyte populations. We emphasize considerations for performing these procedures in the context of a multicenter clinical trial.
11:15
Assaying Blood Cell Populations of the Drosophila melanogaster Larva
0 Views •
Cited by 72 •
2015
Drosophila blood cells, or hemocytes, cycle between resident sites and circulation. In the larva, resident (sessile) hemocytes localize to inductive microenvironments, the Hematopoietic Pockets, while circulating hemocytes move freely in the hemolymph. The goal of this protocol is the standardized isolation and quantification of these two, behaviorally distinct but interchanging, hemocyte populations.
06:14
The Micronucleus Assay on Cryopreserved Whole Blood
0 Views •
Cited by 4 •
2024
Here we present an optimized protocol for the cytokinesis-block micronucleus assay on cryopreserved whole blood samples. This optimized method of cryopreservation of whole blood for micronucleus analysis is a reliable technique for large-scale sampling and multi-center studies and can be used for other blood-related assays as well.
FAQs
Physiological relevance comes from retaining interactions among blood cells, plasma proteins, and soluble factors during testing. These components can contribute collectively to responses triggered by a stimulus, therapeutic compound, or engineered material. Measuring the resulting changes in this preserved environment helps researchers evaluate biological effects under conditions that reflect the integrated blood system more closely than isolated measurements.
Each addition creates a defined condition for observing blood responses. A stimulus can be used to examine immune or inflammatory changes, while a therapeutic compound or engineered material can be evaluated for its effects on blood-related processes. Comparing measured changes across these conditions supports assessment of biological activity, compatibility, and potential safety concerns.
Flow cytometry, immunoassays, and hematological analysis provide complementary ways to quantify assay outcomes. Flow cytometry can support measurements of cellular responses, immunoassays can assess biochemical or immune signals, and hematological analysis can characterize blood-related changes. Selecting among these approaches depends on whether the study focuses on cellular, biochemical, immune, or hematological effects.
A typical workflow starts with an anticoagulated blood sample, followed by incubation with a selected stimulus, therapeutic compound, or engineered material. After incubation, researchers quantify the resulting changes using flow cytometry, immunoassays, or hematological analysis. This sequence links a defined exposure condition to measurable cellular, biochemical, immune, or blood-related outcomes.
Researchers can apply this assay when developing drug-delivery systems, biomaterials, medical devices, or diagnostic technologies. The approach helps examine how these engineered products affect inflammation, coagulation, immune activation, or blood compatibility. Such information supports design decisions aimed at improving safety and performance before technologies are advanced further in development.
The assay can generate data on inflammation, coagulation, immune activation, and blood compatibility after exposure to an engineered material or therapeutic compound. These outcomes help identify biological responses associated with a candidate design and provide evidence for comparing safety and performance across development conditions. The same framework also supports evaluation of diagnostic technologies and delivery systems.